Semaglutide vs tirzepatide side effects compared: common nausea and GI issues, how often they occur, how long they last, and when to call your doctor.
Semaglutide and tirzepatide cause largely the same side effects - nausea, diarrhea, vomiting, and constipation are the most common - and most people tolerate both drugs once the body adjusts. The main mechanical difference is that tirzepatide activates two gut-hormone receptors (GIP and GLP-1) instead of one, and its gastrointestinal effects appeared at similar or slightly different rates in separate clinical trials. Neither medication is risk-free, and a licensed prescriber should review your health history before you start either one.
Semaglutide vs Tirzepatide: Two Drugs, One Side-Effect Family
Any semaglutide vs tirzepatide comparison should begin with what the two drugs share. Both are once-weekly injectables in the incretin class that slow stomach emptying and reduce appetite, and both are FDA-approved in the United States for type 2 diabetes and chronic weight management.
- Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist. Injectable doses go up to 2.0 mg for diabetes and 2.4 mg for weight management.
- Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. Doses go up to 15 mg weekly.
Because they act on overlapping pathways, the tirzepatide side effects reported in trials closely mirror those of semaglutide. Both are prescription-only, and compounded versions sold online are not FDA-approved.
Common Side Effects: How the Rates Compare
The table below summarizes the most frequently reported adverse events from the STEP trials (semaglutide 2.4 mg) and the SURMOUNT trials (tirzepatide 5-15 mg). These were separate studies with different populations, so the numbers are approximations rather than a true head-to-head comparison.
| Side effect | Semaglutide (typical range) | Tirzepatide (typical range) |
|---|---|---|
| Nausea | About 20-44% | About 24-33% |
| Diarrhea | About 20-30% | About 18-23% |
| Vomiting | About 10-24% | About 8-10% |
| Constipation | About 11-24% | About 11-17% |
| Abdominal pain | Up to about 20% | About 6-10% |
| Injection-site reactions | About 2-5% | About 2-6% |
| Fatigue | Commonly reported | Commonly reported |
| Burping, reflux, or sulfur burps | Reported | Reported |
Most of these effects are mild to moderate, show up during the first weeks of treatment or right after a dose increase, and fade as the body adapts. Treatment discontinuation due to side effects was roughly 4-7% in both drug programs, which suggests overall tolerability is comparable.
Is One Drug Harder on Your Stomach Than the Other?
Across trials, neither drug is clearly gentler. Tirzepatide's dual mechanism can produce stronger appetite suppression, and some patients report more nausea at higher tirzepatide doses, but the data do not show a consistent winner.
What matters more than the molecule is the dose and how quickly you climb to it:
- Both drugs are titrated in 4-week steps, and most side effects cluster around each increase.
- Higher maintenance doses generally mean more gastrointestinal symptoms.
- People who skip meals, eat high-fat foods, or drink alcohol tend to report worse nausea.
Anecdotal comparisons are everywhere online - forum threads about tirzepatide vs semaglutide side effects reddit users share reflect individual experiences, not average risk.
Serious Side Effects That Are Less Common
Rare but serious complications have been reported with both medications, and each carries a boxed warning.
- Pancreatitis - severe, persistent upper abdominal pain that may radiate to the back.
- Gallbladder disease - gallstones or cholecystitis, especially with rapid weight loss.
- Bowel obstruction or ileus - uncommon, but reported with GLP-1-based drugs.
- Severe hypoglycemia - mainly when either drug is combined with insulin or sulfonylureas.
- Kidney injury - usually from dehydration caused by vomiting or diarrhea.
- Aspiration risk during anesthesia - tell your surgeon and anesthesiologist that you take either medication.
- Thyroid C-cell tumors - seen in rodents; both drugs are contraindicated for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome.
Do these drugs cause cancer in humans?
Questions about semaglutide side effects cancer risk come up often because of the rodent thyroid findings and a few observational studies. So far, large human trials have not confirmed an increased risk of thyroid cancer, and regulators have kept both drugs on the market while continuing to monitor safety data. A personal or family history of medullary thyroid cancer or MEN2 syndrome remains a hard contraindication.
How Long Do the Side Effects Last?
One of the most common questions is how long do semaglutide side effects last. For most people, nausea and other gastrointestinal symptoms peak in the first one to two weeks after starting or increasing a dose and improve within a few days to a few weeks.
Some people have lingering low-grade nausea for months, and a small percentage cannot tolerate the drug at all. If symptoms are severe, do not push through - your prescriber can lower the dose, slow the titration schedule, or switch medications.
Practical tips for managing side effects
- Eat smaller meals and stop before you feel overly full.
- Limit fried, greasy, and very spicy foods, plus alcohol.
- Prioritize lean protein and sip fluids throughout the day.
- Avoid lying down right after eating.
- Ask your prescriber about anti-nausea medication if symptoms interfere with daily life.
When to Call a Healthcare Professional
Contact your prescriber promptly if you develop severe or worsening abdominal pain, vomiting that keeps you from holding down fluids, signs of dehydration, yellowing of the eyes or skin, or blood sugar readings that are dangerously low or high.
This article is general information, not medical advice. Your prescriber knows your history and can weigh the benefits and risks of semaglutide, tirzepatide, or another option for you.
Frequently Asked Questions
Which has fewer side effects, Ozempic or Mounjaro?
In separate trials, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) showed a similar overall side-effect profile, with nausea, diarrhea, and constipation leading the list for both. Roughly 4-7% of participants in each drug program stopped treatment because of side effects. Tirzepatide has not been proven gentler, and higher doses of either drug tend to cause more gastrointestinal symptoms.
How long do side effects from semaglutide or tirzepatide usually last?
Most gastrointestinal side effects appear within the first week or two of starting the drug or after a dose increase, and they usually ease within days to weeks. Some people have mild nausea that lingers for months, and a small number cannot tolerate the medication at all. Your prescriber can slow the titration or lower the dose if symptoms persist.
Are the serious risks different between semaglutide and tirzepatide?
Both drugs carry a boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome. Pancreatitis, gallbladder disease, bowel obstruction, and severe hypoglycemia have been reported with both. Human data have not confirmed an increased thyroid cancer risk with either medication.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.